Latest News

Cellink AB to take-over Discover Echo Inc

© Discover Echo Inc.


by tg

Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.

San Diego-based Discover Echo Inc. is  a specialist for unique hybrid automated microscopes that easily transform between upright (for viewing glass slides) and inverted configurations (for viewing live samples in petri dishes and well plates), merging the capabilities of multiple instruments into one. Cellink expects the company, which has a subsidiary in the UK, to grow 65% in 2021 and generate about $20m in revenues.

Discover Echo has a large growth potential in the bioprocessing industry where the CELLINK Group is a well-known supplier and has the ability to accelerate Discover Echo’s penetration in this sector. The US company has improved the usability of their microscopes by replacing traditional eyepieces with ultra high-resolution touchscreen displays and offering an intuitive software app that advances the workflow of acquiring, sharing, and analysing images.

"With the strategic acquisition of Discover Echo, we further strengthen our position within our Biosciences segment and we further complement our existing bioconvergence products and capture strong cross-selling synergies,” said Erik Gatenholm, CEO of Cellink AB.

G7 heads call for decarbonisation of industry

The G7 ministers underlined the importance of efforts to improve energy efficiency, the need for increased investment in renewable energy, tracking...

Meat consumption must fall by at least 75 percent

The study from lead author Prof. Dr Matin Qaim reviews the current state of research on various aspects of meat consumption. In addition to the...

International Vaccine Institute – IVI – will locate its European office in Stockholm

The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified...

Switzerland shows sustained growth of biotech sector

Capital investments in Swiss biotech companies reached the second-best amount ever with CHF3.33bn in the second year of the pandemic, according to...

GSK acquires Sierra Oncology for 1.9bn

GSK is paying $1.9 bn in cash ($55 per share) for the deal. This is a 39 per cent premium to the Sierra share price on 12 April and a 63 per cent...

Orphan drug developer Minoryx raises €51m

The Series C round was co-led by Columbus Venture Partners and Caixa Capital Risc, and supported by CDTI Innvierte, Fund+, Ysios Capital and other...

From waste to sugar - demonstration plant opens in Wales

The project’s 11-strong European consortium secured €7m funding from Circular bio-based Europe JU (formerly Bio Based Industries Joint Undertaking)...